Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new vaccine shield teens from meningitis?

NCT ID NCT06700148

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an experimental vaccine designed to protect against four strains of the bacteria that cause meningococcal meningitis, a serious infection of the brain and spinal cord. The study involves around 840 participants aged 7 to 17, who will receive either the new vaccine or a standard one. The goal is to see if the new vaccine safely triggers a strong immune response and offers lasting protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector)
What this could lead to
If successful, this vaccine could offer broader, longer-lasting protection against meningococcal meningitis in children and teens, potentially reducing outbreaks.
What could go wrong
The trial is still in Phase 3, and results may not confirm superior protection. As with any vaccine, there is a risk of side effects, though the study is designed to monitor safety closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

840 people

The number who actually took part.

Started

Dec 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

7 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 7\~17 years old at the time of screening * Volunteers and their legal guardians or delegates have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete 180 days of study follow-up * Willingness to discuss medical history with the investigator or physician and to allow access to all medical records related to this trial Exclusion Criteria: * Fever on the day of vaccination, axillary temperature \>37.0°C * Have a moderate or severe acute illness/infection * Positive urine pregnancy test for females of childbearing age, or plan to become pregnant within 30 days after vaccination * Current meningitis or history of meningitis * Allergy to certain components or excipients of the drugs used in this clinical trial (mainly including: group A meningococcal podoplanoside, group C meningococcal podoplanoside, group Y meningococcal podoplanoside, group W135 meningococcal podoplanoside, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate) * History of epilepsy, convulsions or seizures or history or family history of psychiatric disorders * Previous severe allergic reactions due to drugs or vaccines * Bleeding constitution or condition associated with prolonged bleeding, which in the opinion of the investigator makes intramuscular injection contraindicated * Any meningococcal vaccine in the last 1 year * Any other vaccine within 14 days * Participation in other studies involving interventional studies within 28 days (\<28 days) prior to study entry and/or during study participation * Other conditions that, in the judgment of the investigator, make participation in this clinical trial unsuitable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningococcal meningitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dengfeng Center for Disease Control and Prevention

    Dengfeng, China

  • Kaifeng Center for Disease Control and Prevention

    Kaifeng, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.